Document Detail


Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA.
MedLine Citation:
PMID:  20068403     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The symposium on Antibodies as Drugs, organized by Keystone Symposia and chaired by J. Marks, (University of California Los Angeles, USA), E.S. Ward (University of Texas Southwestern Medical Center, USA) and L. Weiner (Georgetown University Medical Center, USA), was held in Whistler, British Columbia. This Canadian Rockies village, which will host the 2010 Olympic Games, served as an enchanting backdrop to the meeting. The more than 350 speakers and attendees included scientists from major pharmaceutical firms, e.g., Abbott, MedImmune/Astra Zeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi-Aventis, Schering, GlaxoSmithKline, Eli Lilly, Hoffmann LaRoche, Novartis, Wyeth, and biotechnology companies, e.g., Ablynx, Medarex, Morphosys, GenMab, Amgen, Genentech, ImmunoGen, Agensys, Domantis, Biogen Idec, Centocor, LFB, Micromet, PDL Biopharma, Borean Pharma, Dyax Corp., Symphogen and Syntonix. Academic research groups at Imperial College London, University of Oxford, ETH Zürich, Scripps, Institute Cochin, Karolinska Institute, Utrecht University, Harvard Medical School, Massachusetts Institute of Technology, Baylor College, Paul Ehrlich Institute, University of California San Francisco, University of California San Diego, University of Nantes, University of Tours and Ludwig Institute were also represented, as were regulatory authorities, including the US Food and Drug Administration, National Institutes of Health and the Public Health Agency of Canada). The meeting was very interactive and included thoughtful exchanges during the different sessions and networking events.
Authors:
Thierry Wurch; Christel Larbouret; Bruno Robert
Related Documents :
3959933 - Combined premedical-medical programmes: programme structure and student outcomes at fou...
17984863 - Ilizarow's external fixator in clinical use. ten years of using the method at the depar...
1191823 - Automatic and manual indexing performance in a small file of medical literature.
Publication Detail:
Type:  Congresses     Date:  2009-07-28
Journal Detail:
Title:  mAbs     Volume:  1     ISSN:  1942-0870     ISO Abbreviation:  MAbs     Publication Date:    2009 Jul-Aug
Date Detail:
Created Date:  2010-01-13     Completed Date:  2010-04-16     Revised Date:  2010-11-16    
Medline Journal Info:
Nlm Unique ID:  101479829     Medline TA:  MAbs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  318-25     Citation Subset:  IM    
Affiliation:
Centre d'Immunologie Pierre FABRE, Saint Julien en Genevois 74164, France. thierry.wurch@pierre-fabre.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Bispecific / pharmacology,  therapeutic use
Antibodies, Monoclonal / pharmacology,  therapeutic use*
Canada
Mutation
Neoplasms / drug therapy*
Tumor Suppressor Protein p53 / drug effects*,  genetics
Chemical
Reg. No./Substance:
0/Antibodies, Bispecific; 0/Antibodies, Monoclonal; 0/Tumor Suppressor Protein p53
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglob...
Next Document:  Ofatumumab.